Condition
Antiemetic
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 3 (1)
P 4 (1)
Trial Status
Unknown2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05564286Phase 3Completed
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
NCT04576390Phase 4UnknownPrimary
Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCP
NCT00502437Not ApplicableUnknown
The Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental Situations
Showing all 3 trials